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Abstract
Problem/Condition: Acquired immunodeficiency syndrome (AIDS)-defining oppor-
tunistic illnesses (OIs) are the major cause of morbidity and mortality among persons
infected with human immunodeficiency virus (HIV). As a result of new treatments that
reduce mortality for persons with AIDS, the number of persons living with AIDS is
increasing, and the incidence of AIDS is decreasing. In 1997, an estimated 271,245 per-
sons were living with AIDS in the United States and thus were at high risk for OIs. In
1997, an estimated 21,909 HIV-infected persons died with AIDS, nearly all as a result of
OIs.
Reporting Period Covered: Aggregate data and trends for 1992–1997 were exam-
ined to determine a) the frequencies at which OIs occurred first; b) the incidence of
OIs; c) the percentage of persons among those who have died who had had a given OI
during their course of AIDS, and d) the frequency of prescriptions for antiretroviral
therapy and prophylaxis for Pneumocystis carinii pneumonia (PCP) and for Mycobac-
terium avium complex disease (MAC).
Description of System: Data were analyzed from the Adult/Adolescent Spectrum of
HIV Disease (ASD) sentinel surveillance project, a prospective medical record review
of HIV-infected persons aged ≥13 years conducted in 11 U.S. cities. ASD data were
standardized to national AIDS surveillance data for 1992–1997 by age; race; sex; coun-
try of birth; year of AIDS diagnosis; HIV exposure mode; and for incidence
calculations, by CD4+ T-lymphocyte distribution.
Results: The incidence declined significantly for each of 15 of the 26 specific AIDS-
defining OIs (p<0.05). PCP was the most common AIDS-defining OI to occur first (PCP
was the first OI to occur for 36% of HIV-infected persons), the most common incident
AIDS-defining OI (274 cases per 1000 person-years), and the most common AIDS-
defining OI to have occurred during the course of AIDS (53% of persons who died with
AIDS had PCP diagnosed at some time during their course of AIDS). Of persons with
CD4+ T-lymphocyte counts <500 cells/µL, the number with prescriptions for triple com-
bination therapy increased from zero in 1992 to 40% in 1997, and 80% of persons had
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a prescription for any antiretroviral therapy in 1997. Of persons with CD4+ T-lympho-
cyte counts <200 cells/µL, the percentage with prescriptions for PCP prophylaxis
remained stable from 1992 through 1997 (range: 75% to 80%). Of persons with CD4+
T-lymphocyte counts <50 cells/µL, the percentage with prescriptions for MAC prophy-
laxis increased from 9% in 1992 to 44% in 1997.
Interpretations: The incidences of many OIs are decreasing primarily because of
advances in HIV-related therapy. However, OIs are still occurring, especially when pa-
tients access care late during the course of disease. Even after accessing care, persons
may develop OIs because of lack of prescription for prophylaxis, antiretroviral drug
resistance, or poor adherence to therapy. During 1992–1997, most patients in need of
PCP prophylaxis received a prescription for it; however, even in 1997, most patients in
need of MAC prophylaxis did not receive a prescription for it.
Actions Taken: These surveillance data are used by persons involved with develop-
ing guidelines for preventing OIs to determine the importance of and trends in OIs and
preventive therapy. CDC is developing population-based approaches for surveillance
of HIV disease progression, OIs, and therapies with the goal of making these data
available in more geographic areas to help assess public health and health-care
programs.
INTRODUCTION
Acquired immunodeficiency syndrome (AIDS)-defining opportunistic illnesses
(OIs) are the major cause of morbidity and mortality among human immunodeficiency
virus (HIV)-infected persons. As a result of new treatments that improve outcomes for
HIV-infected persons, the prevalence of AIDS is increasing (1 ). In 1997, an estimated
271,245 persons were living with AIDS in the United States and thus were at high risk
for OIs (1 ). In 1997, an estimated 21,909 HIV-infected persons died with AIDS, nearly
all from OIs.
The incidence of major OIs (2–4 ) and the percentage of HIV-infected persons with
various OIs during a specified period have been documented (5 ). However, few stud-
ies have reported the occurrence of each AIDS-defining OI during the course of AIDS
(6,7 ). Such analyses are helpful for determining the preventive medications and treat-
ments needed for HIV-infected persons. In addition, examination of the frequencies
and trends in the AIDS-defining OIs first to occur can assist in determining the first
severe and potentially preventable life-threatening event encountered by HIV-infected
persons. To determine the frequencies and trends in the OIs first to occur, the inci-
dence of OIs, and the OIs that occurred during the course of AIDS, data were analyzed
from the CDC-sponsored Adult/Adolescent Spectrum of HIV Disease (ASD) sentinel
surveillance project.
METHODS
ASD was implemented by CDC in collaboration with state and local health depart-
ments to monitor the spectrum and frequency of HIV-associated illnesses. Data
collection started in 1990. The methods for ASD have been described previously (8 ).
At selected sites in Denver, Colo.; Los Angeles, Calif.; Atlanta, Ga.; New Orleans, La.;
Detroit, Mich.; New York, N.Y.; Dallas, Houston, and San Antonio, Tex.; Seattle, Wash.;
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and Bayamon, Puerto Rico, HIV-infected persons aged ≥13 years are identified at their
first health-care encounter in an ASD clinic, regardless of the stage of their HIV infec-
tion. Approximately 100 medical facilities that provide inpatient and/or outpatient care
for HIV-infected patients were included in this analysis. The facilities comprised public
(73%) and private (27%) institutions.
All HIV-infected persons who attend participating clinics are eligible for enrollment.
To prevent oversampling of certain groups relative to the national population with
AIDS, sampling of patients for inclusion is conducted at some sites: 50% of African
American males in Atlanta since January 1994; 25%–50% of white males in Dallas, San
Antonio, and selected sites in Seattle since 1990–1991; no white males (except
injecting-drug users [IDUs]) at some Los Angeles sites since 1992; 40%–50% of all men
at Detroit sites since 1993; and 16%–50% of white males at some New York City sites
since January 1995.
Information is collected about demographic characteristics, mode of HIV exposure,
and any previous occurrences of conditions listed in the 1993 AIDS surveillance case
definition (9 ). ASD data are reported to CDC without personal identifying information.
During successive 6-month follow-up intervals, medical records are reviewed for ill-
nesses, AIDS-defining conditions, prescriptions, laboratory tests (including CD4+
T-lymphocyte tests), and use of medical care. The CDC hierarchical classification is
used for HIV exposure mode (1 ). OIs were defined by using the clinical AIDS condi-
tions in the 1993 AIDS surveillance case definition (9 ). Definitive and presumptive
diagnoses were combined for this analysis. Cytomegalovirus (CMV) retinitis was ana-
lyzed separately from other CMV disease. For ASD, lost to follow-up was defined as
unable to locate a patient for ≥18 months; during 1992–1997, 15.5% of ASD partici-
pants were lost to follow-up.
Frequencies at Which OIs Occurred First
The frequencies at which AIDS-defining OIs occurred first were calculated by ana-
lyzing cases diagnosed with clinical AIDS from 1992 through 1997 and reported to the
ASD project through June 1998. The results are reported as the percentage of persons
with any AIDS-defining OI who had a given OI as the first OI. The numerator for each
OI is the number of persons for which that OI occurred first, and the denominator is all
persons with at least one OI. The percentages for all 26 AIDS-defining OIs add to more
than 100% because a person may have had more than one OI occur first. In this analy-
sis, ASD data were weighted by age, race, country of birth (United States or foreign),
year of AIDS diagnosis, sex, and HIV exposure mode (except when examining year-,
sex-, and exposure-specific strata, respectively). The standard population used in the
weighting process was defined as persons who had AIDS diagnosed in the United
States during 1992–1997 and who were reported to CDC AIDS surveillance through
June 1998. The national AIDS surveillance data used for the standard population were
adjusted for reporting delays (10 ). The number of AIDS-defining OIs for each year in
the standard population was estimated by the sum of the reported OIs and the pre-
dicted OIs under the immunologic criteria (11 ).
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Incidence of OIs
The incidence of the first occurrence of each AIDS-defining OI for persons in the
ASD population was calculated as a rate per 1,000 person-years. The first occurrence
of a specific OI was defined as the initial diagnosis of that OI (i.e., it could be the first,
second, or any subsequent diagnosis in a series of different OIs). Data were weighted
using a procedure similar to that described for the frequencies at which OIs occurred
first, except the CD4+ T-lymphocyte distribution was included when weighting to the
standard population. The distribution of CD4+ T-lymphocyte counts used in the stand-
ard population was obtained from CDC national AIDS surveillance data for 1994–1997
because reporting of CD4+ counts was most complete during these years compared
with previous years. Using this CD4+ T-lymphocyte distribution emphasizes the inci-
dence of AIDS-defining OIs at CD4 counts that occur in the range at which AIDS
typically occurs.
Percentage of Persons with Specific OIs During the Course
of AIDS
The percentage of persons with specific OIs during the course of AIDS was calcu-
lated by analyzing cases among persons who died from 1992 through 1997 and who
were reported to the CDC ASD project through June 1998. For this calculation, the
numerator was the number of persons who ever had a given OI, and the denominator
was the number of persons who died with one or more AIDS-defining OIs from 1992
through 1997. The standard population for the percentage of persons with specific OIs
diagnosed during the course of AIDS was defined as persons with AIDS who died
during 1992–1997 who were recorded in national AIDS surveillance and who were
reported to CDC through June 1998. The national AIDS surveillance data used for the
standard population were adjusted for delays in reporting deaths. Data were weighted
using a procedure similar to that described for the frequencies at which OIs occurred
first.
Frequencies of Prescriptions for Antiretroviral Therapy
and Prophylaxis for Pneumocystis carinii Pneumonia
and Mycobacterium avium Complex Disease
Trends in prescribing antiretroviral therapy were assessed for persons with CD4+
T-lymphocyte counts <500 cells/µL. Triple combination therapy was defined as two
nucleoside analogue reverse transcriptase inhibitors combined with a protease inhibi-
tor or nonnucleoside reverse transcriptase inhibitor as recommended in the
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(12 ). Dual combination therapies assessed were zidovudine combined with didanos-
ine, zalcitabine, or lamivudine and stavudine combined with didanosine or
lamivudine. Monotherapies were defined as zidovudine, didanosine, or stavudine.
Trends in prescribing medications for primary prophylaxis of Pneumocystis carinii
pneumonia (PCP) (trimethoprim-sulfamethoxazole [TMP-SMZ], dapsone, or aerosol-
ized pentamidine) were assessed for persons with CD4+ T-lymphocyte counts
<200 cells/µL. Trends in prescribing primary prophylaxis for Mycobacterium avium
complex disease (MAC) (rifabutin, clarithromycin, or azithromycin) were assessed for
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persons with CD4+ T-lymphocyte counts <50 cells/µL. Data about treatment and pro-
phylaxis were weighted using a procedure similar to that described for the incidence
calculations.
Data were analyzed using SAS software (13 ). Trends were examined and frequen-
cies and incidence rates by sex and HIV exposure mode were compared using the
stratified Cochran-Mantel-Haenszel statistic.
RESULTS
Frequencies at Which OIs Occurred First
From January 1992 through December 1997, AIDS-defining OIs were diagnosed in
12,982 HIV-infected persons. Of these, 10,658 (82%) were males, and 2,324 (18%) were
females. The percentage of males with an AIDS-defining OI for whom a given OI oc-
curred first ranged from zero (for chronic isosporiasis) to 35.7% (for PCP) (Table 1).
Similarly, the percentage of women with an AIDS-defining OI for whom a given OI
occurred first ranged from zero (for chronic isosporiasis, Burkitts lymphoma, and re-
current Salmonella septicemia) to 33.7% (for PCP) (Table 2).
The frequency at which AIDS-defining OIs occurred first varied by sex. For exam-
ple, for males, the OIs more likely to occur first were Kaposi sarcoma (KS),
extrapulmonary cryptococcosis, and CMV disease (Table 1). For females, the OIs more
likely to occur first were esophageal candidiasis, recurrent pneumonia, pulmonary tu-
berculosis (TB), and chronic herpes simplex (Table 2). However, among IDUs,
pulmonary TB was more likely to occur first among males than among females.
The frequency at which AIDS-defining OIs occurred first also varied by HIV expo-
sure mode (Tables 1 and 2). The OIs that occurred first more frequently among men
who have sex with men (MSM) were KS, CMV retinitis, CMV disease, and chronic
cryptosporidiosis. However, the OIs that occurred first more frequently among both
male IDUs and males exposed to HIV through heterosexual contact were pulmonary
TB, extrapulmonary TB, recurrent pneumonia, toxoplasmosis of the brain, and
disseminated histoplasmosis. In addition, chronic herpes simplex and disseminated
coccidioidomycosis occurred first more frequently among men exposed to HIV
through heterosexual contact. There were few statistically significant differences in
the frequency at which OIs occurred first between female IDUs and females exposed
to HIV through heterosexual contact. However, toxoplasmosis of the brain occurred
first more frequently among females exposed to HIV through heterosexual contact,
and immunoblastic lymphoma occurred first more frequently among female IDUs
(values in Table 2 are rounded).
During 1992–1997, the frequency at which OIs occurred first increased for five OIs
and decreased for five OIs (Table 3). The frequency at which PCP occurred first re-
mained constant during this period, and the frequency at which esophageal
candidiasis occurred first increased.
Incidence of OIs
Overall, 22,558 HIV-infected persons (17,404 [77%] males and 5,154 [23%] females)
were followed 35,933 person-years; 6,113 persons had incident OIs. The incidence of
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TABLE 1. Percentage* of males with at least one acquired immunodeficiency
syndrome-defining opportunistic illness (OI) for whom a given OI occurred first, by
disease and human immunodeficiency virus (HIV) exposure mode† —
















pneumonia 35.7 34.6 35.4 35.1
Kaposi sarcoma¶   12.5** 15.0   2.0**  3.7
Esophageal candidiasis   11.9†† 11.0  15.5†† 15.2
Wasting syndrome  7.8 7.7 10.6  6.9
Mycobacterium avium 
complex  6.4 6.6 6.2  9.5
Pulmonary tuberculosis¶    4.8†† 3.1  13.7**  8.1
Extrapulmonary
cryptococcosis    4.3** 4.0 4.4  4.6
HIV encephalopathy  4.2 4.3 3.3  3.2
Cytomegalovirus retinitis¶  3.8 4.4 1.6  1.6
Cytomegalovirus disease¶    3.4** 4.1 0.9    0.7††
Toxoplasmosis of brain¶  2.9 2.3   6.7**  5.1
Chronic cryptosporidiosis¶  2.9 3.3 0.7  1.1
Recurrent pneumonia¶    2.3†† 1.8   4.9††  5.0
Extrapulmonary tuberculosis¶  2.0 1.6 4.6  4.6
Chronic herpes simplex¶    2.0†† 1.9   1.6††  2.9
Immunoblastic lymphoma  1.6 1.9 0.7  0.7
Progressive multifocal
leukoencephalopathy  1.1 1.2 0.8  0.9
Disseminated
histoplasmosis¶  0.7 0.7 0.9  2.1
Burkitts lymphoma  0.7 1.0 0.0  0.5
Other disseminated
Mycobacterium  0.6 0.6 0.8  0.3
Primary brain lymphoma  0.4 0.5 0.4  0.0
Pulmonary candidiasis  0.3 0.2 0.8  0.3
Disseminated
coccidioidomycosis¶  0.1 0.1 0.1  0.4
Recurrent Salmonella 
septicemia  0.1 0.1 0.3  0.4
Chronic isosporiasis  0.0 0.0 0.0  0.0
 *Data for each opportunistic illness are standardized to the sex- or risk-specific proportion
of national acquired immunodeficiency syndrome surveillance cases by age, race, year of
diagnosis, and country of birth. Data from all cities are weighted equally.
†Data in this analysis are for the three largest single HIV exposure modes for males observed
in the Adult/Adolescent Spectrum of HIV Disease project. Exposure mode-specific data are
not presented for 2,457 males with other HIV exposure modes.
§A CDC-sponsored surveillance project that collects data at selected sites in 11 U.S. cities.
¶Di f ferences  by HIV exposure mode were signif icant  using the s trat i fied
Cochran-Mantel-Haenszel (CMH) statistic (p<0.05).
**In a comparison of data in Tables 1 and 2, the difference by sex for this item was significant
using the stratified CMH statistic; the percentage was higher for males (p<0.05).
††In a comparison of data in Tables 1 and 2, the difference by sex for this item was significant
using the stratified CMH statistic; the percentage was higher for females (p<0.05).
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TABLE 2. Percentage* of females with at least one acquired immunodeficiency
syndrome-defining opportunistic illness (OI) for whom a given OI occurred first, by
disease and human immunodeficiency virus (HIV) exposure mode† —












Pneumocystis carinii  pneumonia 33.7 32.2 35.1 
Esophageal candidiasis  19.9¶  19.8¶ 19.6 
Wasting syndrome 9.0 9.6 8.3
Recurrent pneumonia  7.1¶  10.2¶ 4.2
Mycobacterium avium  complex 6.8 5.1 8.2
Pulmonary tuberculosis  6.6¶    8.3** 5.3
Chronic herpes simplex  4.1¶  4.6¶ 3.8
Toxoplasmosis of brain†† 3.8    2.4** 5.6
Cytomegalovirus retinitis 3.4 2.9 3.8
HIV encephalopathy 3.2 3.5 3.0
Extrapulmonary cryptococcosis   3.1** 3.2 3.0
Extrapulmonary tuberculosis 3.0 4.2 1.9
Cytomegalovirus disease   2.1** 1.6  2.5¶
Chronic cryptosporidiosis 1.5 0.9 2.0
Kaposi sarcoma   1.3**    1.2** 1.3
Disseminated histoplasmosis 1.1 1.1 1.0
Invasive cervical cancer 0.9 1.0 0.8
Progressive multifocal
leukoencephalopathy 0.9 1.0 0.7
Pulmonary candidiasis 0.5 0.7 0.4
Other disseminated
Mycobacterium 0.4 0.3 0.4
Disseminated coccidioidomycosis 0.4 0.3 0.6
Primary brain lymphoma 0.3 0.1 0.5
Immunoblastic lymphoma†† 0.1 0.1 0.1
Chronic isosporiasis 0.0 0.0 0.0
Burkitts lymphoma 0.0 0.0 0.0
Recurrent Salmonella  septicemia 0.0 0.0 0.0
 *Data for each opportunistic illness is standardized to the sex- or risk-specific proportion of
national acquired immunodeficiency syndrome surveillance cases by age, race, year of
diagnosis, and country of birth. Data from all cities are weighted equally.
†Data in this analysis are for the two largest HIV exposure modes for females observed in
the Adult/Adolescent Spectrum of HIV Disease project. Exposure mode-specific data are not
presented for 627 females with other HIV exposure modes.
§A CDC-sponsored surveillance project that collects data at selected sites in 11 U.S. cities.
¶In a comparison of data in Tables 1 and 2, the difference by sex for this item was significant
using the stratified Cochran-Mantel-Haenszel (CMH) statistic; the percentage was higher for
females (p<0.05).
**In a comparison of data in Tables 1 and 2, the difference by sex for this item was significant
using the stratified CMH statistic; the percentage was higher for males (p<0.05).
††Differences by HIV exposure mode were significant using the stratified CMH statistic
(p<0.05).
















TABLE 3. Percentage* of persons with at least one acquired immunodeficiency syndrome-defining opportunistic illness (OI)
















(N=798) Trend§  
Pneumocystis carinii  pneumonia 35.9 36.6 35.0 34.7 34.7 38.1 42.6 none
Esophageal candidiasis 12.4 11.5 11.4 11.2 14.1 14.8 15.0 increasing
Kaposi sarcoma 11.6 11.1 12.0 11.6 13.2 9.5 10.7 none
Wasting syndrome 7.8 10.5 6.1 5.8 7.2 8.4 12.2 increasing
Mycobacterium avium  complex 6.4 5.7 5.7 8.2 7.2 5.6 4.8 decreasing
Pulmonary tuberculosis 5.0 6.4 5.9 5.2 3.7 2.6 3.6 decreasing
Extrapulmonary cryptococcosis 4.3 4.0 5.0 3.8 4.6 4.3 3.8 none
HIV encephalopathy 4.2 3.8 4.7 4.1 3.5 5.1 3.6 none
Cytomegalovirus retinitis 3.7 3.4 3.8 4.3 3.5 4.0 2.6 none
Cytomegalovirus disease 3.2 3.7 2.7 3.1 4.0 3.3 1.1 none
Toxoplasmosis of brain 3.0 2.9 3.0 3.0 3.1 3.3 2.6 none
Chronic cryptosporidiosis 2.7 1.8 3.2 3.2 3.1 2.8 1.5 none
Recurrent pneumonia 2.5 2.1 2.7 2.5 2.5 2.8 3.0 none
Extrapulmonary tuberculosis 2.1 2.6 2.4 2.0 1.8 1.2 0.9 decreasing
Chronic herpes simplex 2.1 2.4 3.1 1.7 1.8 1.3 0.5 decreasing
Immunoblastic lymphoma 1.5 1.2 1.4 2.3 0.8 2.1 1.9 increasing
Progressive multifocal
leukoencephalopathy 1.0 0.5 0.7 1.5 1.3 1.6 0.7 increasing
Invasive cervical cancer¶ 0.9 1.1 0.5 1.5 1.1 0.1 0.9 none
Disseminated histoplasmosis 0.7 0.9 0.7 0.7 0.7 0.3 1.0 none
Burkitts lymphoma 0.7 0.6 0.7 0.7 0.4 0.9 1.5 none
Other disseminated
Mycobacterium 0.6 1.2 0.6 0.4 0.3 0.5 0.4 decreasing
Primary brain lymphoma 0.4 0.6 0.3 0.6 0.3 0.3 0.1 none
Pulmonary candidiasis 0.3 0.2 0.6 0.4 0.2 0.2 0.2 none
Disseminated coccidioidomycosis 0.1 0.0 0.1 0.0 0.0 0.4 0.7 increasing
Recurrent Salmonella  septicemia 0.1 0.1 0.1 0.1 0.0 0.2 0.0 none
Chronic isosporiasis 0.0 0.0 0.1 0.0 0.0 0.0 0.1 none
*Data for each opportunistic illness are standardized to national acquired immunodeficiency syndrome surveillance cases by age, race,
country of birth, sex, and human immunodeficiency virus (HIV) exposure mode. Data from all cities are weighted equally.
†A CDC-sponsored surveillance project that collects data at selected sites in 11 U.S. cities.
§The direction of change is given for trends that were significant (p<0.05) based on the stratified (HIV exposure mode, race, sex, age,
metropolitan area, and country of birth) Cochran-Mantel-Haenszel statistic.
¶Restricted to women.
AIDS-defining OIs varied by sex. Overall, the incidences of KS, CMV disease, and ex-
trapulmonary cryptococcosis were higher in males than in females (Tables 4 and 5);
however, among IDUs and persons exposed to HIV through heterosexual contact, the
incidence of CMV disease was higher in females than in males. Overall, the incidences
of pulmonary TB, chronic herpes simplex disease, and extrapulmonary TB were
higher in females than in males. However, among IDUs, the incidence of extrapulmon-
ary TB was higher in males than in females.
The incidence of AIDS-defining OIs also varied by HIV exposure mode (Tables 4 and
5). The incidences of MAC, CMV retinitis, KS, CMV disease, and chronic crypto-
sporidiosis were higher for MSM than for other male groups. However, the incidences
of PCP, recurrent pneumonia, toxoplasmosis of the brain, pulmonary TB, and extrapul-
monary TB were higher for male IDUs and males exposed to HIV through
heterosexual contact (except PCP) than for MSM. The incidences of any OI (combined)
and of esophageal candidiasis were higher for female IDUs than females exposed to
HIV through heterosexual contact. The incidence of CMV retinitis was higher for fe-
males with a heterosexual HIV exposure risk than for female IDUs.
During 1992–1997, the incidence decreased significantly for any AIDS-defining OI
(combined) and for 15 of the 26 specific AIDS-defining OIs (p<0.05) (Table 6). Even for
many OIs without statistically significant declines over all years, incidences declined
in 1997. For example, in 1997, incidences declined for esophageal candidiasis, recur-
rent pneumonia, progressive multifocal leukoencepalopathy, immunoblastic
lymphoma, primary brain lymphoma, and disseminated histoplasmosis. No signifi-
cant increases in incidence occurred during 1992–1997. In general, the largest
decreases in incidence occurred during the most recent years.
Percentage of Persons with Specific OIs 
During the Course of AIDS
During 1992–1997, a total of 10,353 HIV-infected persons observed in the ASD pro-
ject died with AIDS. Of these, 8,811 (85%) were males, and 1,542 (15%) were females.
Overall, the percentages of males who ever had a given OI during the course of AIDS
ranged from 0.1% (for chronic isosporiasis) to 52.8% (for PCP) (Table 7). Overall, the
percentages of females who ever had a given OI during the course of AIDS ranged
from zero (for Burkitts lymphoma and chronic isosporiasis) to 52.2% (for PCP) (Table
8). OIs diagnosed more frequently among males than among females were KS, CMV
retinitis, CMV disease, extrapulmonary cryptococcosis, and toxoplasmosis of the
brain (Tables 7 and 8). However, for IDUs, CMV disease was diagnosed more fre-
quently among females than among males. Overall, OIs diagnosed more frequently
among females than among males were esophageal candidiasis, pulmonary TB, and
chronic herpes simplex. However, for IDUs and persons exposed to HIV through het-
erosexual contact, pulmonary TB was diagnosed more frequently among males than
among females.
The frequency of OIs during the course of AIDS also varied by sex and HIV expo-
sure mode. For example, MAC, KS, CMV retinitis, CMV disease, and chronic
cryptosporidiosis were diagnosed more frequently among MSM than among other
groups of men (Table 7). However, male IDUs had pulmonary TB and extrapulmonary
TB diagnosed more frequently than other groups of men. There were few significant
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TABLE 4. Incidence* of acquired immunodeficiency syndrome-defining opportunistic
illnesses (OIs) among males, by disease and human immunodeficiency virus (HIV)















Any OI 277.0 281.2 271.6 284.6 
Pneumocystis carinii 
pneumonia¶ 87.8 86.2 97.2 81.0
Mycobacterium avium 
complex¶ 77.9 81.4 54.7 70.3
Esophageal candidiasis 57.6 54.6 76.3 65.8
Cytomegalovirus retinitis¶ 53.9 61.7 18.7 33.9
Kaposi sarcoma¶   48.7** 56.6   10.4** 14.3
Wasting syndrome 50.6 52.2 53.9 52.7
HIV encephalopathy 35.0 35.4 22.4 32.9
Cytomegalovirus disease¶   34.2** 40.0    7.8††   10.3††
Recurrent pneumonia¶ 19.5 18.1 30.3 31.8
Extrapulmonary
cryptococcosis   16.2** 15.3   16.8** 19.3
Chronic cryptosporidiosis¶ 14.7 16.7  4.9 12.3
Toxoplasmosis of brain¶ 13.7 12.7 21.5 24.8
Pulmonary tuberculosis¶   10.5††  8.4 24.7   15.2**
Chronic herpes simplex¶    9.8††  9.1    8.0†† 11.1
Progressive multifocal
leukoencephalopathy  9.2 10.0  7.2  2.7
Extrapulmonary tuberculosis¶    7.5††  6.5   14.3** 13.7
Immunoblastic lymphoma  7.1  7.9    4.4**  0.7
Other disseminated
Mycobacterium  6.7  7.3   5.9  5.0
Primary brain lymphoma  5.5  5.9   2.2  2.2
Disseminated histoplasmosis  3.5  3.5   3.5 10.9
Pulmonary candidiasis  2.2  2.5   2.2  2.7
Burkitts lymphoma  1.4  1.7   0.1  0.0
Disseminated
coccidioidomycosis¶  0.5  0.4   0.1    1.8**
Chronic isosporiasis¶  0.2  0.1   0.0  0.1
Recurrent Salmonella 
septicemia  0.2  0.3   0.1  0.0
 *Per 1,000 person-years standardized to the sex- or risk-specific proportion of national
acquired immunodeficiency syndrome surveillance cases by age, race, year of diagnosis,
country of birth, and CD4+ T-lymphocyte distribution. Data from all cities are weighted
equally.
†Data in this analysis are for the three largest single HIV exposure modes for males observed
in the Adult/Adolescent Spectrum of HIV Disease project. Exposure mode-specific data are
not presented for 3,928 males with other HIV exposure modes.
§A CDC-sponsored surveillance project that collects data at selected sites in 11 U.S. cities.
¶Di f ferences  by HIV exposure mode were signif icant  using the s trat i fied
Cochran-Mantel-Haenszel (CMH) statistic (p<0.05).
**In a comparison of data in Tables 4 and 5, the difference by sex for this item was significant
using the stratified CMH statistic; the incidence rate was higher for males (p<0.05).
††
In a comparison of data in Tables 4 and 5, the difference by sex for this item was significant
using the stratified CMH statistic; the incidence rate was higher for females (p<0.05).
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TABLE 5. Incidence* of acquired immunodeficiency syndrome-defining opportunistic
illnesses among females, by disease and human immunodeficiency (HIV) exposure











Any OI¶ 249.5 266.6 231.7 
Pneumocystis carinii 
pneumonia 85.9 89.8 82.2
Esophageal candidiasis¶ 70.4 76.4 65.6
Mycobacterium avium  complex 55.9 54.7 55.9
Wasting syndrome 50.4 53.5 47.7
Recurrent pneumonia 34.2 40.0 28.1
Cytomegalovirus retinitis¶ 27.2 21.1 32.5
HIV encephalopathy 25.7 21.8 28.3
Pulmonary tuberculosis   17.7** 22.9   13.7††
Chronic herpes simplex   17.7**   11.1** 17.9
Cytomegalovirus disease   16.4††   16.4**   16.3**
Extrapulmonary cryptococcosis   12.7††   13.1†† 13.0
Toxoplasmosis of brain 11.6  9.2 14.6
Extrapulmonary tuberculosis    8.2**    7.6††  8.7
Chronic cryptosporidiosis  8.1  7.4  8.5
Other disseminated
Mycobacterium  6.9  7.8  6.1
Kaposi sarcoma    5.2††    4.8††  5.3
Progressive multifocal
leukoencephalopathy  5.3  7.1  3.4
Invasive cervical cancer  2.8  3.4  2.1
Disseminated histoplasmosis  2.5  2.7  2.5
Pulmonary candidiasis  1.6  2.3  1.0
Primary brain lymphoma  1.3  1.0  1.4
Disseminated
coccidioidomycosis  1.2  1.9    0.4††
Immunoblastic lymphoma  1.1    0.2††  1.9
Recurrent Salmonella
septicemia  0.2  0.1  0.2
Burkitts lymphoma  0.1  0.1  0.1
Chronic isosporiasis  0.0  0.0  0.1
 *Per 1,000 person-years standardized to the sex- or risk-specific proportion of national
acquired immunodeficiency syndrome surveillance cases by age, race, year of diagnosis,
country of birth, and CD4+ T-lymphocyte distribution. Data from all cities are weighted
equally.
†Data in this analysis are for the two largest HIV exposure modes for females observed in
the Adult/Adolescent Spectrum of HIV Disease project. Exposure mode-specific data are not
presented for 1,554 females with other HIV exposure modes.
§A CDC-sponsored surveillance project that collects data at selected sites in 11 U.S. cities.
¶Di f ferences  by HIV exposure mode were signif icant  using the s trat i fied
Cochran-Mantel-Haenszel (CMH) statistic (p<0.05).
**In a comparison of data in Tables 4 and 5, the difference by sex for this item was significant
using the stratified CMH statistic; the incidence rate was higher for females (p<0.05).
††In a comparison of data in Tables 4 and 5, the difference by sex for this item was significant
using the stratified CMH statistic; the incidence rate was higher for males (p<0.05).

















TABLE 6. Incidence* of acquired immunodeficiency syndrome-defining opportunistic illnesses, by disease and year of
















Any OI 273.9 327.2 277.8 304.7 269.2 215.0 147.7 decreasing
Pneumocystis carinii  pneumonia 87.9 108.3 91.9 87.6 94.1 66.7 45.5 decreasing
Mycobacterium avium  complex 76.6 101.4 85.1 78.6 73.0 59.7 15.6 decreasing
Esophageal candidiasis 58.7 61.2 58.3 59.7 60.2 64.6 32.3 none
Cytomegalovirus retinitis 51.2 66.2 58.0 54.1 48.4 35.2 17.4 decreasing
Wasting syndrome 50.0 65.5 51.3 44.1 52.2 40.5 32.0 decreasing
Kaposi sarcoma 45.0 60.6 42.6 50.9 44.4 30.7 19.7 decreasing
HIV encephalopathy 34.8 39.6 38.0 35.4 36.7 27.4 18.6 decreasing
Cytomegalovirus disease 32.3 45.3 29.3 33.6 33.8 23.5 12.8 decreasing
Recurrent pneumonia 20.2 22.0 19.1 25.6 19.3 16.7 10.7 none
Extrapulmonary cryptococcosis 16.3 18.4 17.2 16.4 14.6 16.9 10.4 decreasing
Chronic cryptosporidiosis 14.1 16.4 15.1 17.9 11.4 12.0  3.7 decreasing
Toxoplasmosis of brain 13.7 20.7 15.2 14.7 10.2  8.2  7.0 decreasing
Pulmonary tuberculosis 11.1 16.2 12.1 11.1  9.3  4.3 11.0 decreasing
Chronic herpes simplex 10.3 17.5 12.0  9.8  7.6  5.0  2.8 decreasing
Progressive multifocal
leukoencephalopathy  8.9  9.7  8.2  8.8 10.9  9.5  2.7 none
Extrapulmonary tuberculosis  7.7 11.7  9.5  7.2  6.5  4.5  1.8 decreasing
Immunoblastic lymphoma  6.7  6.2  7.9  6.8  6.4  6.7  4.7 none
Other disseminated Mycobacterium  6.6 11.2  8.9  4.5  5.2  3.9  2.0 decreasing
Primary brain lymphoma  5.2  6.6  4.5  8.0  4.2  3.5  1.1 none
Disseminated histoplasmosis  3.5  5.0  2.8  4.5  2.1  3.5  1.8 none
Invasive cervical cancer**  3.0  0.0  1.8  9.0  0.5  2.5  2.6 none
Pulmonary candidiasis  2.0  3.5  1.9  2.3  2.0  0.4  0.2 decreasing
Burkitts lymphoma  1.3  0.5  2.7  1.2  1.1  0.3  2.3 none
Disseminated coccidioidomycosis  0.5  0.8  0.2  0.4  0.0  0.6  1.8 none
Chronic isosporiasis  0.2  0.1  0.4  0.0  0.2  0.2  0.0 none
Recurrent Salmonella  septicemia  0.2  0.0  0.4  0.4  0.2  0.1  0.0 none
 *Per 1,000 person-years standardized to national acquired immunodeficiency syndrome surveillance cases by age, race, country of




A CDC-sponsored surveillance project that collects data at selected sites in 11 U.S. cities.
 
§
N=number of persons at risk for any AIDS-defining OI; number of persons varies for each disease.
 
¶
The direction of change is given for trends that were significant (p<0.05) based on the stratified (CD4+ T-lymphocyte count, HIV
exposure mode, race, sex, age, metropolitan area, and country of birth) Cochran-Mantel-Haenszel statistic.
TABLE 7. Percentage* of persons with specific opportunistic illnesses during the
course of acquired immunodeficiency syndrome for male decedents, by disease and
human immunodeficiency virus (HIV) exposure mode† — Adult/Adolescent Spectrum

















Pneumocystis carinii  pneumonia 52.8 52.1 52.9 45.0
Mycobacterium avium  complex¶ 30.2 31.7 19.2 22.7
Esophageal candidiasis   24.1** 23.5   28.1** 24.4
Kaposi sarcoma¶   23.8†† 27.4    4.1††  5.4
Cytomegalovirus retinitis¶   21.3†† 24.2  6.7 11.9
Wasting syndrome 20.8 20.9 22.8 19.6
HIV encephalopathy¶ 11.6 13.8  9.2 13.1
Cytomegalovirus disease¶   13.4†† 15.4    3.0**     2.5**
Extrapulmonary cryptococcosis¶    8.1††  7.6  9.0   13.9††
Recurrent pneumonia  7.2  6.9  9.0 13.0
Toxoplasmosis of brain¶    7.1††  6.8   10.6†† 13.0
Pulmonary tuberculosis¶    6.4**  4.8   18.5††   13.5††
Chronic cryptosporidiosis¶  6.0  6.6    2.3**  4.7
Chronic herpes simplex    4.7**  4.6    4.0**  5.1
Extrapulmonary tuberculosis¶  4.0  3.2  9.0  5.3
Other disseminated Mycobacterium  3.3  3.6  2.4  1.5
Immunoblastic lymphoma  3.1  3.4    1.5††  1.3
Progressive multifocal
leukoencephalopathy  2.7  2.9  2.2  2.0
Primary brain lymphoma  2.2  2.4  1.0  1.0
Disseminated histoplasmosis  1.6  1.6  1.8  1.9
Pulmonary candidiasis  1.0  1.1  1.0  0.7
Burkitts lymphoma  0.9  1.1  0.1  0.4
Disseminated coccidioidomycosis  0.2  0.2  0.0  0.4
Recurrent Salmonella  septicemia¶  0.2  0.2  0.4  1.1
Chronic isosporiasis  0.1  0.1  0.0  0.0
 *The numerator is the number of persons who ever had a specific opportunistic illness (OI);
the denominator is the number of persons who died with one or more acquired
immunodeficiency syndrome (AIDS)-defining OIs during 1992–1997. These data are
standardized to the sex- or risk-specific proportion of national AIDS deaths by age, race,
year of death, and country of birth. Data for all cities are weighted equally.
†Data in this analysis are for the three largest single HIV exposure modes for males observed
in the Adult/Adolescent Spectrum of HIV Disease project. Exposure mode-specific data are
not presented for 1,880 males with other HIV exposure modes.
§A CDC-sponsored surveillance project that collects data at selected sites in 11 U.S. cities.
¶Di f ferences  by HIV exposure mode were signif icant  using the s trat i fied
Cochran-Mantel-Haenszel (CMH) statistic (p<0.05).
** In a comparison of data in Tables 7 and 8, the difference by sex for this item was significant
using the stratified CMH statistic; the percentage was higher for females (p<0.05).
††In a comparison of data in Tables 7 and 8, the difference by sex for this item was significant
using the stratified CMH statistic; the percentage was higher for males (p<0.05).
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TABLE 8. Percentage* of persons with specific opportunistic illnesses during the
course of acquired immunodeficiency syndrome for female decedents, by disease and
human immunodeficiency virus (HIV) exposure mode† — Adult/Adolescent Spectrum













Pneumocystis carinii  pneumonia 52.2 52.8 51.1
Esophageal candidiasis  34.2¶  34.8¶ 33.3
Mycobacterium avium  complex 26.2 24.1 27.7
Wasting syndrome 24.3 23.6 25.5
Recurrent pneumonia  12.7¶  13.6¶ 11.5
Pulmonary tuberculosis**  11.8¶   14.4††    8.4††
HIV encephalopathy 11.6 10.4 13.1
Cytomegalovirus retinitis**   11.2††  9.2 14.1
Cytomegalovirus disease    8.1††   8.5¶   7.6¶
Chronic herpes simplex   8.0¶   8.5¶  7.7
Toxoplasmosis of brain    6.9††    5.4††  9.2
Extrapulmonary tuberculosis  6.6  8.0  4.7
Extrapulmonary cryptococcosis    5.9††  6.9    4.9††
Chronic cryptosporidiosis  4.5   4.0¶  5.0
Other disseminated Mycobacterium  3.2  3.3  3.0
Progressive multifocal
leukoencephalopathy  2.6  2.9  2.0
Kaposi sarcoma    2.3††    2.3††  2.6
Disseminated histoplasmosis  2.0  2.1  1.7
Invasive cervical cancer  1.9  2.5  1.0
Pulmonary candidiasis  1.0  1.2  0.8
Primary brain lymphoma  0.9  0.3  1.6
Immunoblastic lymphoma  0.5    0.1††  0.9
Recurrent Salmonella  septicemia  0.3  0.3  0.2
Disseminated coccidioidomycosis  0.2  0.1  0.2
Burkitts lymphoma  0.0  0.0  0.1
Chronic isosporiasis  0.0  0.0  0.1
 *The numerator is the number of persons who ever had a specific opportunistic illness (OI);
the denominator is the number of persons who died with one or more acquired
immunodeficiency syndrome (AIDS)-defining OIs during 1992–1997. These data are
standardized to the sex- or risk-specific proportion of national AIDS deaths by age, race,
year of death, and country of birth. Data for all cities are weighted equally.
†Data in this analysis are for the two largest HIV exposure modes for females observed in
the Adult/Adolescent Spectrum of HIV Disease project. Exposure mode-specific data are not
presented for 363 females with other HIV exposure modes.
§A CDC-sponsored surveillance project that collects data at selected sites in 11 U.S. cities.
¶In a comparison of data in Tables 7 and 8, the difference by sex for this item was significant
using the stratified Cochran-Mantel-Haenszel (CMH) statistic; the percentage was higher for
females (p<0.05).
**Differences by HIV exposure mode were significant using the stratified CMH statistic
(p<0.05).
††In a comparison of data in Tables 7 and 8, the difference by sex for this item was significant
using the stratified CMH statistic; the percentage was higher for males (p<0.05).
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differences in the frequency of OIs during the course of AIDS among women (Table 8).
However, pulmonary TB was diagnosed more frequently among female IDUs, and
CMV retinitis was diagnosed more frequently among females exposed to HIV through
heterosexual contact.
For many AIDS-defining OIs, the annual percentage of persons with specific OIs
during the course of AIDS remained constant during 1992–1997 (Table 9). However,
the percentage decreased for persons who ever had PCP, toxoplasmosis of the brain,
extrapulmonary TB, disseminated non-MAC Mycobacterium, and pulmonary candidi-
asis, and the percentage increased for persons who ever had wasting syndrome,
recurrent pneumonia, or pulmonary TB. The median number of unique AIDS-defining
OIs per person during the course of AIDS was two (25th percentile, one unique AIDS-
defining OI; 75th percentile, three unique AIDS-defining OIs) (range: 1–10 unique
AIDS-defining OIs).
Frequencies of Prescriptions for Antiretroviral Therapy 
and Prophylaxis for PCP and MAC
From 1992 through 1997, among persons with CD4+ T-lymphocyte counts
<500 cells/µL, prescription of dual combination therapy increased from 22% to 32%,
and prescription of triple combination therapy increased from zero to 40% (Figure 1).
During this period, prescription of monotherapy decreased from 58% to 7% (Figure 1).
Among persons with CD4+ T-lymphocyte counts <200 cells/µL, prescriptions to pre-
vent PCP remained relatively stable (75%–80%), but the percentage of persons
receiving TMP-SMZ increased from 1992 through 1995 (from 57% to 64%) (Figure 2).
Although prescriptions to prevent MAC increased each year during 1993–1997 among
persons with CD4+ T-lymphocyte counts <50 cells/µL (Figure 3), most (56%) of these
severely immunosuppressed HIV-infected persons still had not had this medication
prescribed in 1997.
DISCUSSION
During 1992–1997, PCP was the most common AIDS-defining OI to occur first
(36%), the most common incident AIDS-defining OI, and the most common AIDS-
defining OI to have occurred among persons who had died with AIDS. The incidence
of PCP decreased, and the percentage of persons who ever had PCP during the course
of AIDS decreased. However, previous analyses in ASD during this period indicated
that PCP remained the most common OI to occur first because of a) delays in diagno-
sis of HIV infection and in access to care for some groups, b) occurrence despite use
of prophylaxis at low CD4+ T-lymphocyte counts, and c) probable lack of compliance
with prophylaxis (14 ). Previous analyses in ASD also have indicated that up to 50% of
PCP cases occur in persons who have not been tested for HIV or who have not ac-
cessed care (14 ). In the current analysis, the percentage of PCP that ever occurred
among persons who had died with AIDS was substantially lower (53% during 1992–
1997 and 43% in 1997) than that found in 1990 and before (67%) (6 ). The recommend-
ations for PCP prophylaxis were promulgated in 1989 (15 ) and probably account for
much of the decline in the incidence of PCP. The percentage of persons with prescrip-
tions for TMP-SMZ increased from 57% in 1992 to 64% in 1995 and remained relatively

















TABLE 9. Percentage* of persons with specific opportunistic illnesses during the course of acquired immunodeficiency
















Pneumocystis carinii  pneumonia 53.0 57.9 55.6 51.7 47.2 52.6 43.4 decreasing
Mycobacterium avium  complex 30.0 31.9 29.6 28.3 30.9 30.3 23.1 none
Esophageal candidiasis 24.4 24.6 24.5 21.5 25.8 26.9 30.1 none
Kaposi sarcoma 22.6 25.0 24.9 22.2 19.6 19.1 20.5 none
Wasting syndrome 20.8 22.9 21.5 17.8 20.7 20.7 27.5 increasing
Cytomegalovirus retinitis 20.6 21.3 21.2 20.3 20.2 19.7 18.9 none
HIV encephalopathy 13.5 14.1 12.1 15.1 14.0 11.3 11.4 none
Cytomegalovirus disease 12.9 15.7 12.6 10.7 13.0 12.9 12.9 none
Extrapulmonary cryptococcosis  8.1  8.4  9.0  6.6  8.3  8.7  9.1 none
Recurrent pneumonia  7.4  5.7  6.9  8.7  8.5  6.9  8.0 increasing
Toxoplasmosis of brain  7.2  9.3  7.3  7.1  5.8  5.7  5.7 decreasing
Pulmonary tuberculosis  6.8  5.2  5.8  8.4  7.7  6.7  7.3 increasing
Chronic cryptosporidiosis  5.9  5.9  5.3  6.0  6.6  5.8  5.8 none
Chronic herpes simplex  4.9  4.6  5.2  5.0  4.7  4.7  3.5 none
Extrapulmonary tuberculosis  4.1  4.2  4.4  4.2  4.4  3.0  1.6 decreasing
Other disseminated Mycobacterium  3.3  3.9  4.3  3.0  2.2  2.6  1.8 decreasing
Immunoblastic lymphoma  3.0  3.1  3.0  2.4  3.2  2.8  6.0 none
Progressive multifocal
leukoencephalopathy  2.7  2.6  2.3  2.7  2.9  3.1  1.8 none
Primary brain lymphoma  2.1  1.9  1.8  2.3  2.5  1.8  1.7 none
Invasive cervical cancer¶  2.0  2.0  1.0  2.5  1.9  2.9  1.6 none
Disseminated histoplasmosis  1.6  2.3  1.9  1.3  1.4  1.1  1.7 none
Pulmonary candidiasis  1.0  1.1  0.9  1.1  1.1  0.4  0.1 decreasing
Burkitts lymphoma  0.9  0.6  1.2  1.0  0.5  1.0  0.7 none
Disseminated coccidioidomycosis  0.2  0.1  0.2  0.2  0.1  0.3  0.1 none
Recurrent Salmonella  septicemia  0.2  0.3  0.4  0.1  0.1  0.1  0.0 none
Chronic isosporiasis  0.1  0.1  0.1  0.1  0.1  0.1  0.0 none
*The numerator is the number of persons who ever had a given opportunistic illness (OI); the denominator is the number of persons
who died with one or more acquired immunodeficiency syndrome (AIDS)-defining OIs during 1992–1997. These data are standardized
to national AIDS deaths by age, race, country of birth, sex, and human immunodeficiency virus (HIV) exposure mode. Data for all cities
are weighted equally.
†A CDC-sponsored surveillance project that collects data at selected sites in 11 U.S. cities.
§The direction of change is given for trends that were significant (p<0.05) based on the stratified (HIV exposure mode, race, sex, age,
metropolitan area, and country of birth) Cochran-Mantel-Haenszel statistic.
¶Restricted to women.
stable thereafter (Figure 2). TMP-SMZ is easy to administer and is effective at prevent-
ing PCP (16 ). Since late 1995, triple combination antiretroviral therapy probably has
had a substantial impact on PCP (and other OIs) by slowing the progression of HIV
disease. Other studies indicate a substantial reduction from January 1994 through
June 1997 in the incidence of PCP and other OIs associated with an increase in combi-
nation therapy (including protease inhibitors) (17 ). However, PCP still occurs,
particularly among persons who were tested late for HIV or who failed to access care
(18–21 ).
In addition, the incidence of toxoplasmic encephalitis decreased, and the percent-
age of persons who had toxoplasmic encephalitis diagnosed during the course of
AIDS decreased. These decreases are probably a result of PCP prophylaxis with TMP-
SMZ, a medication that also prevents toxoplasmic encephalitis (22–24 ). The
frequency at which toxoplasmosis occurred first has remained relatively stable over
time. Reasons for this lack of decline may be similar to the reasons for the lack of
decline in the frequency at which PCP occurred first (i.e., late HIV testing and failure to
access care). Prophylaxis for toxoplasmic encephalitis was recommended in 1995 for
adults and adolescents seropositive for Toxoplasma and with CD4+ T-lymphocyte





















*A CDC-sponsored surveillance project that collects data at selected sites in 11 U.S. cities.
FIGURE 1. Percentage of persons with CD4+ T-lymphocyte counts <500 cells/µL who
had antiretroviral therapy (ART) prescribed, by year — Adult/Adolescent Spectrum
of HIV Disease project,* 1992–1997
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During 1992–1997, both the frequency at which MAC occurred first and the inci-
dence of MAC decreased, but the percentage of persons who had MAC diagnosed
during the course of AIDS remained stable. MAC prophylaxis and antiretroviral ther-
apy probably have contributed to the decline in the incidence of MAC, but occurrence
at low CD4+ T-lymphocyte counts (despite prescription of prophylaxis) and poor com-
pliance with therapy may result in eventual development of MAC in some persons.
MAC prophylaxis was first recommended in 1993 for adults and adolescents with
CD4+ T-lymphocyte counts <75 cells/µL (26 ); the recommendations were updated in
1997 to limit use in adults and adolescents to those with CD4+ T-lymphocyte counts
<50 cells/µL (27 ).
The findings that the rates of esophageal candidiasis and chronic herpes simplex
were higher for females than for males have been noted previously (28–31 ). Higher
rates of esophageal candidiasis may occur in women because of vaginal colonization
with Candida (29 ). Higher rates of herpes simplex may occur in women because the
disease is more common in female IDUs than in male IDUs (32 ). Researchers have
suggested that the exchange of sex or money for drugs may be more common among
female than among male IDUs, resulting in a higher rate of sexually transmitted dis-
eases (including herpes simplex virus infection) among women (33,34 ).
In addition, rates of TB were higher for females than for males. Injecting-drug use




















*Trimethoprim-sulfamethoxazole (TMP-SMX), dapsone, or aerosolized pentamidine.
†A CDC-sponsored surveillance project that collects data at selected sites in 11 U.S. cities.
FIGURE 2. Percentage of persons with CD4+ T-lymphocyte counts <200 cells/µL who
had prophylaxis for Pneumocystis carinii pneumonia* prescribed, by year —
Adult/Adolescent Spectrum of HIV Disease project,† 1992–1997
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proportion of women than men are IDUs, women are more likely to have TB. However,
among IDUs only, the rates of TB generally were higher for males than for females.
Rates of KS, CMV disease, and CMV retinitis were higher for males than for fe-
males. These diseases are associated with sexual transmission, and a larger
proportion of men than women have sexual HIV risks. However, the higher rate of
CMV disease among female IDUs than male IDUs may be associated with the practice
of exchange of sex for money or drugs.
The findings in this report are subject to at least four limitations associated with the
ASD data. First, ASD data may not be complete because illnesses in general are not
always diagnosed and, even when diagnosed, are not always recorded in the medical
chart. However, because AIDS-defining OIs are serious medical conditions, they usu-
ally are recorded in the chart. Second, because ASD does not represent the entire
population of persons in the United States with HIV infection and AIDS, these findings
may not be generalizable to the entire U.S. population. The frequency of some OIs
(e.g., TB and coccidioidomycosis) varies by region. However, ASD has a large patient
population enrolled from a diverse group of clinics and hospitals nationwide. Third,
medications recorded in ASD are those prescribed any time during each 6-month data
abstraction interval, regardless of the duration of treatment. The reasons for prescrib-





















*Rifabutin, clarithromycin, or azithromycin.
†A CDC-sponsored surveillance project that collects data at selected sites in 11 U.S. cities.
FIGURE 3. Percentage of persons with CD4+ T-lymphocyte counts <50 cells/µL who
had prophylaxis for Mycobacterium avium  complex* prescribed, by year —
Adult/Adolescent Spectrum of HIV Disease project,† 1992–1997
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ASD may exclude diagnoses that occur outside the enrolled hospitals and clinics.
However, whenever possible, hospital and clinic staff attempt to obtain medical re-
cords from other facilities to help ensure optimal patient care.
Many persons are enrolled in ASD when their first OI occurs, and they may not
have medical care before their first major illness. As a result, preventable OIs occur in
ASD patients at a higher frequency than in populations in which most patients obtain
care early during the course of HIV disease. One previous study in ASD indicated that,
for IDUs, incidences have not decreased as frequently or for as many OIs as for MSM
(35 ).
Persons at risk for HIV infection must receive HIV testing and access medical care
before onset of advanced immunosuppression. This enables administration of
chemoprophylaxis to prevent OIs, vaccinations to prevent illnesses (e.g., pneumo-
coccal disease), and antiretroviral treatment to prevent progression and the serious
manifestations of HIV-related disease. In addition, the progression of HIV infection to
AIDS should be monitored. Antiretroviral drug resistance and poor adherence to
medications can substantially increase the rate of disease progression. Surveillance
for severe HIV-related illnesses will continue to be essential in determining how well
HIV-related morbidity is being prevented.
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